Docoh
Loading...

LEGN Legend Biotech

Filed: 12 May 21, 1:54pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: May 12, 2021

Commission File Number: 001-39307

 

 

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

 

 

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


Legend Biotech Announces Abstracts for Upcoming 2021 ASCO and EHA Meetings

On May 12, 2021, Legend Biotech Corporation announced that several abstracts have been accepted at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2021 Virtual Congress.

The press release is attached to this Form 6-K as Exhibit 99.1.

EXHIBIT INDEX

 

Exhibit

  

Title

99.1  Press Release, dated May 12, 2021.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  

LEGEND BIOTECH CORPORATION

(Registrant)

May 12, 2021

  

By:

  

/s/ Ying Huang

    Ying Huang, Ph.D.
    Chief Executive Officer and Chief Financial Officer